{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31414593", "DateCompleted": {"Year": "2020", "Month": "09", "Day": "21"}, "DateRevised": {"Year": "2021", "Month": "02", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "08", "Day": "26"}], "Language": ["eng"], "ELocationID": ["10.1021/acs.chemrestox.9b00141"], "Journal": {"ISSN": "1520-5010", "JournalIssue": {"Volume": "32", "Issue": "9", "PubDate": {"Year": "2019", "Month": "Sep", "Day": "16"}}, "Title": "Chemical research in toxicology", "ISOAbbreviation": "Chem Res Toxicol"}, "ArticleTitle": "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.", "Pagination": {"StartPage": "1791", "EndPage": "1800", "MedlinePgn": "1791-1800"}, "Abstract": {"AbstractText": ["Tofacitinib (TFT) is an oral JAK inhibitor which has been approved for the treatment of moderately and severely active rheumatoid arthritis. TFT was found to show concentration-, time-, and NADPH-dependent inhibition of CYP3A4, and irreversibility of the inactivation was also observed. Incubation (40 min, 37 \u00b0C) of recombinant CYP3A4 with TFT at 200 \u03bcM resulted in >70% loss of CYP3A4 activity. Estimated <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> were 0.037 min<sup>-1</sup> and 93.2 \u03bcM, respectively. GSH and superoxide dismutase/catalase revealed minor or little protection against the CYP3A4 inactivation. Furthermore, ketoconazole attenuated TFT-mediated CYP3A4 inactivation. Epoxide and \u03b1-keto-aldehyde intermediates of TFT were trapped and characterized in microsomal incubations, respectively. The aldehyde intermediate is believed to be the key for the enzyme inactivation. Multiple P450 enzymes, including CYPs2C19, 3A4, 2D6, and 1A2, participated in the metabolism of TFT to the epoxide, while the formation of the aldehyde was mainly catalyzed by CYP3A4. In conclusion, TFT was proven to be a mechanism-based inactivator of CYP3A4."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Guo", "ForeName": "Xiucai", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Li", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Li", "ForeName": "Qingmei", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Chen", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Zhao", "ForeName": "Guode", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Peng", "ForeName": "Ying", "Initials": "Y"}, {"Identifier": ["0000-0002-0340-0275"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province , Guizhou Medical University , Guiyang , Guizhou 550004 , P. R. China."}], "LastName": "Zheng", "ForeName": "Jiang", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Chem Res Toxicol", "NlmUniqueID": "8807448", "ISSNLinking": "0893-228X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cytochrome P-450 CYP3A Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrroles"}, {"RegistryNumber": "53-59-8", "NameOfSubstance": "NADP"}, {"RegistryNumber": "87LA6FU830", "NameOfSubstance": "tofacitinib"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP3A"}, {"RegistryNumber": "EC 1.14.14.55", "NameOfSubstance": "CYP3A4 protein, human"}, {"RegistryNumber": "R9400W927I", "NameOfSubstance": "Ketoconazole"}], "CommentsCorrectionsList": [{"RefSource": "Chem Res Toxicol. 2020 Feb 17;33(2):281-282. doi: 10.1021/acs.chemrestox.9b00455", "PMID": "31833760"}, {"RefSource": "Chem Res Toxicol. 2020 Jul 20;33(7):1514-1515. doi: 10.1021/acs.chemrestox.0c00187", "PMID": "32469513"}], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Cytochrome P-450 CYP3A"}, {"QualifierName": ["chemical synthesis", "pharmacology"], "DescriptorName": "Cytochrome P-450 CYP3A Inhibitors"}, {"QualifierName": [], "DescriptorName": "Enzyme Assays"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Ketoconazole"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects"], "DescriptorName": "Microsomes, Liver"}, {"QualifierName": ["metabolism"], "DescriptorName": "NADP"}, {"QualifierName": ["chemical synthesis", "pharmacology"], "DescriptorName": "Piperidines"}, {"QualifierName": ["chemical synthesis", "pharmacology"], "DescriptorName": "Pyrimidines"}, {"QualifierName": ["chemical synthesis", "pharmacology"], "DescriptorName": "Pyrroles"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2019", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "9", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31414593", "10.1021/acs.chemrestox.9b00141"]}}]}